Abstract：
Treatment options have expanded rapidly and widely in the past two decades for patients with multiple myeloma. Triplet novel agent-based induction regimens have been accepted as the standard practice wordwide over the last decade both for transplant-eligible and non-eligible patients. The addition of anti-CD38 monoclonal antibodies as part of quadruplet regimens has led to even deeper and longer-lasting responses. The impressive results shown by the quadruplets havebeen practice-changing where accessible in recent years. Chimeric antigen receptor T cell therapy and bispecific antibodies are being tested in the upfront setting and have the potential to once again shift the paradigm of treatment of newly diagnosed MM.
摘要：
在过去的二十年中，多发性骨髓瘤患者的治疗选择迅速而广泛地扩展。在过去的十年中，对于符合移植资格和不符合移植资格的患者，三联体新的基于药剂的诱导方案已被接受为标准实践。作为四联疗法的一部分，添加抗CD38单克隆抗体导致了更深入和更持久的反应。近年来，四胞胎所表现出的令人印象深刻的结果已经改变了实践。嵌合抗原受体T细胞疗法和双特异性抗体正在预先设置中进行测试，并且有可能再次改变新诊断MM的治疗范式。
